Biomarkers and Sustainable Innovation in Cardiovascular Drug Development: Lessons from Near and Far Afield
- 20 March 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Atherosclerosis Reports
- Vol. 15 (5), 321
- https://doi.org/10.1007/s11883-013-0321-0
Abstract
No abstract availableThis publication has 62 references indexed in Scilit:
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events: MESA (Multi-Ethnic Study of Atherosclerosis)Journal of Invasive Cardiology, 2012
- Molecular-Targeted Therapies in Head and Neck CancerSeminars in Radiation Oncology, 2012
- Treatment selection in metastatic renal cell carcinoma: expert consensusNature Reviews Clinical Oncology, 2012
- The BATTLE to Personalize Lung Cancer Prevention through Reverse MigrationCancer Prevention Research, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe Lancet Oncology, 2010
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003